SCHEMBL427728

SCHEMBL427728

Cc1cccc(C=NNc2nc(N3CCOCC3)c(F)c(OCCN3CCOCC3)c2F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIKFYVE Q9Y2I7 11/20 0.49
KDM4E B2RXH2 4/20 0.49
MAPT P10636 3/20 0.49
LMNA P02545 2/20 0.49
HPGD P15428 1/20 0.49
FES P07332 1/20 0.48
FER P16591 1/20 0.48
TYK2 P29597 1/20 0.48
FRK P42685 1/20 0.48
SYK P43405 1/20 0.48
CAMK1D Q8IU85 1/20 0.48
IRAK4 Q9NWZ3 1/20 0.48
GAA P10253 1/20 0.44
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
MAPK1 P28482 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ALDH1A1 P00352 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL427727 1.00 PIKFYVE (0.49) PIKFYVEKDM4EMAPTLMNAHPGD
SCHEMBL14530478 0.90 PIKFYVE (0.44) PIKFYVEKDM4EMAPTLMNAHPGD
SCHEMBL428807 0.87 PIKFYVE (0.65) PIKFYVEKDM4EMAPTLMNAHPGD
SCHEMBL428808 0.87 PIKFYVE (0.65) PIKFYVEKDM4EMAPTLMNAHPGD
SCHEMBL2671756 0.85 PIKFYVE (0.49) PIKFYVEKDM4EMAPTLMNAHPGD
SCHEMBL2672979 0.85 KDM4E (0.49) PIKFYVEKDM4EMAPTLMNAHPGD
SCHEMBL2671759 0.85 PIKFYVE (0.49) PIKFYVEKDM4EMAPTLMNAHPGD
SCHEMBL2672978 0.85 KDM4E (0.49) PIKFYVEKDM4EMAPTLMNAHPGD
SCHEMBL13758987 0.85 PIKFYVE (0.42) PIKFYVEKDM4EMAPTLMNAHPGD
SCHEMBL427234 0.80 MAPT (0.55) PIKFYVEKDM4EMAPTLMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150174132-A1 METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS SYNTA PHARMACEUTICALS CORP (US) 2015-06-25 US disclosed
US-8173651-B2 Pyridine compounds SYNTA PHARMACEUTICALS CORPORATION (US) 2012-05-08 US disclosed
US-20120021434-A1 METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS SYNTA PHARMACEUTICALS CORP. (US) 2012-01-26 US disclosed
US-20110098267-A1 TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS SYNTA PHARMACEUTICALS CORPORATION (US) 2011-04-28 US disclosed
US-20100173413-A1 PYRIDINE COMPOUNDS SYNTA PHARMACEUTICALS CORPORATION (US) 2010-07-08 US disclosed
US-7687498-B2 Pyridine compounds SYNTA PHARMACEUTICALS CORPORATION (US) 2010-03-30 US disclosed
US-20090163708-A1 PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS SYNTA PHARMACEUTICALS CORP. (US) 2009-06-25 US disclosed
EP-1687004-A4 PYRIDINE COMPOUNDS SYNTA PHARMACEUTICALS CORP (US) 2009-04-08 EP disclosed
US-20080167300-A1 PYRIDINE COMPOUNDS MADRIGAL PHARMACEUTICALS, INC. 2008-07-10 US disclosed
US-7338951-B2 Pyridine compounds SYNTA PHARMACEUTICALS CORP. (US) 2008-03-04 US disclosed
US-20070032493-A1 Method for treating B cell regulated autoimmune disorders SYNTA PHARMACEUTICALS CORP. (US) 2007-02-08 US disclosed
EP-1687004-A2 PYRIDINE COMPOUNDS Synta Pharmaceuticals Corporation (US) 2006-08-09 EP disclosed
US-20050250774-A1 Pyridine compounds LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2005-11-10 US disclosed
WO-2005046603-A2 PYRIDINE COMPOUNDS SYNTA PHARMACEUTICALS, CORP. (US) 2005-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167300-A1 PYRIDINE COMPOUNDS IL2, IL4, IL6 PIKFYVE 1593/4885KDM4E 2452/4885MAPT 1165/4885
US-20110098267-A1 TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS IL17A, IL23R, IL15 PIKFYVE 1824/4885KDM4E 3825/4885MAPT 238/4885
US-20150174132-A1 METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS REL, NFATC1, BCL6 PIKFYVE 4150/4885KDM4E 1015/4885MAPT 4316/4885
US-20100173413-A1 PYRIDINE COMPOUNDS IL2, IL4, IL6 PIKFYVE 1593/4885KDM4E 2452/4885MAPT 1165/4885
US-20050250774-A1 Pyridine compounds IL2, IL4, IL6 PIKFYVE 1593/4885KDM4E 2452/4885MAPT 1165/4885
US-20090163708-A1 PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS IL17A, IL23R, IL2 PIKFYVE 2941/4885KDM4E 2869/4885MAPT 2815/4885
US-20070032493-A1 Method for treating B cell regulated autoimmune disorders REL, NFATC1, BCL6 PIKFYVE 4150/4885KDM4E 1015/4885MAPT 4316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.